Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake Read more
Informing payers and patients of biological therapy advantages can strengthen biosimilars market Read more
Biocon Biologics to get Rs 225 cr from Tata Capital Growth Fund for 0.85 per cent equity stake Read more
Biocon Biologics receives EU GMP Certification for multiple Biosimilars manufacturing facilities in Bengaluru Read more
FDA and FTC announce new efforts to further deter anti-competitive business practices, support competitive market for biological products to help Americans Read more